Menu
PBD Biotech
PBD Biotech has developed a novel phage-based diagnostic technique to detect the presence of mycobacteria infections.
Agricultural biotechnology
School of Biosciences
Profile
PBD Biotech has developed a novel phage-based diagnostic technique to detect the presence of mycobacteria infections.
The test is able to distinguish between viable and non-viable organisms and, unlike currently used tests that monitor an immune response, can therefore reliably differentiate between animals carrying live infectious organisms and those that have been specifically vaccinated.
Whilst existing tests can take weeks to determine a result, making control of the disease difficult, PBD’s test can provide a more reliable result within 8 hours.
News and press releases
@PBDBiotech on Twitter
More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB
Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies
TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair - PBD Biotech
PBD Biotech has appointed Dr Marie Roskrow to chair its board and has expanded its scientific advisory panel ahead of further trials.
bit.ly
Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease
COVID-19 Still a Focus for Infectious Disease Test Developers in 2022, but Ceded Some Ground
Tests for other respiratory viruses, as well as sexually transmitted infections and tuberculosis, moved back into the development pipeline last year.
bit.ly
The long-term goal of this RFP by @FINDdx is to provide tools to accelerate the development of new anti-#tuberculosis drugs and regimens to #EndTB
A shared language can help us to #EndTB. @StopTB has created a brilliant ‘Words Matter’ language guide to bring consensus around the terms that describe the dynamic continuum #tuberculosis infection and crucially to de-stigmatise those impacted @UNITE4TB
Words Matter – how a shared language will accelerate development of TB diagnostics - PBD Biotech
‘Words Matter’ from Stop TB Partnership aims to create a consensus around the terms used to describe the dynamic continuum of TB infection
bit.ly
TB research funding hit $1bn for first time in 2021, after 3 year plateau according to a new report by
@TAGTeam_Tweets @StopTB with 'incredible work in diagnostics' @NIH largest diagnostics funder and @gatesfoundation largest philanthropic funder #EndTB
Worldwide TB R&D Funding Surpasses US$1 Billion, But Falls Short of
New York | December 6, 2022 – For the first time in history, funding for tuberculosis (TB) research and development (R&D) hit a billion dollars worl...
bit.ly
Actiphage only test for subclinical tuberculosis that detects mycobacteria in blood @TAGTeam_Tweets Pipeline Report 2022 reveals of the 10.6m people who developed active TB last year, only 6.4m were diagnosed. A vast unmet need #endTB
TAG Pipeline Report-Actiphage subclinical TB test - PBD Biotech
Actiphage only test for subclinical tuberculosis that directly detects mycobacteria in the blood, TAG Pipeline Report reveals
bit.ly
New Pipeline report @TAGTeam_Tweets says
investment in R&D for TB diagnostics R&D reached an all time high in 2020. Interesting description of 'acoustic epidemiology' AI-based tools that detect and monitor cough & lung sounds as biomarker for TB #EndTB http://bit.ly/3GfTP6W
Gallery
